Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease-Reference-Cited by-同舟云学术

Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease

Published:2013-05-31 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Zheng Guo Hua¹,Liu Jian Ping²,Chu Jian Feng¹,Mei Lijuan¹,Chen Hai Ying³

Affiliation:

1. Fujian University of Traditional Chinese Medicine; Center for Evidence-based Chinese Medicine; No 1, Huatuo Road, University Town Fuzhou Fujian China 350108

2. Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; 11 Bei San Huan Dong Lu, Chaoyang District Beijing China 100029

3. The First Affiliated Hospital, Fujian University of Traditional Chinese Medicine; Department of Cardiology; 602 Middle 817 Road, University Town Gulou District Fujian Fujian China 350004

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD009581.pub2/fullpdf

Reference83 articles.

1. Chen KJ Shi DZ Xu H A multicentre, randomized, double blind, placebo controlled study of Xiongshao capsule preventing restenosis post-PCI operation. Proceeding of the sixth congress of blood stasis syndrome and activate blood stasis to remove stasis study of integrated traditional and western medicine;2005 Agu 19-21;Yanji Beijin China Society of Integrated Traditional Chinese and Western Medicine 2005 23 31

2. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China;Chen;Chin Med J.,2006

3. Chen KJ Shi DZ Xu H Lu XY A multicentre clinical study of Xiongshao capsule preventing restenosis post-PCI Development of traditional Chinese medicine and human health. Proceedings of the first international Forum on Development of Traditional Chinese Medicine (Celebrating 50th birthday of Chinaacademy of traditional Chinese medicine) 2005 Nov 18-20;Beijin Beijin China Academy of Chinese Medical Science 2005 1032 1040

4. A multi-center randomized double-blind placebo-controlled trial of Xiongshao capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients;Shang;Chin J Integr Med,2011

5. XSC on restenosis after percutaneous coronary intervention effects observed.;Liu;China Health Industry,2012

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy of traditional Chinese herbal medicine across multiple cardiovascular diseases: an umbrella review of systematic reviews of randomized controlled trials;Journal of Cardiovascular Pharmacology;2024-01-09

2. Comparative efficacy of different Chinese patent medicines in preventing restenosis after percutaneous coronary intervention: a systematic review and Bayesian network meta-analysis of randomized clinical trials;Frontiers in Pharmacology;2024-01-05

3. Efficacy and safety of Qixue Tongzhi Granule in improving the exercise capacity of stable coronary artery disease: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial;Frontiers in Cardiovascular Medicine;2023-08-17

4. Identification of a Novel Angiogenesis Signalling circSCRG1/miR-1268b/NR4A1 Pathway in Atherosclerosis and the Regulatory Effects of TMP-PF In Vitro;Molecules;2023-01-28

5. Complement use of Chinese herbal medicine after percutaneous coronary intervention: a prospective observational study;J GERIATR CARDIOL;2022